African Journal of Infectious Diseases Research

ISSN 2756-3340

Table of Contents 2025

African Journal of Infectious Diseases Research | Vol. 11, No. 4, April 2025 | pp. 325-336

DOI: 10.46882/AJIDR/148728

Article Type: Research Article

Title: Seroepidemiology and risk factors of Hepatitis C virus infection among patients undergoing maintenance hemodialysis

Names of Authors: Mariam Al-Thani¹*, Kofi Mensah², Giulia Conti³

Authors’ Affiliations: ¹Department of Nephrology, Hamad Medical Corporation, Doha, Qatar. ²Department of Internal Medicine, University of Cape Coast, Cape Coast, Ghana. ³Department of Gastroenterology, Sapienza University of Rome, Rome, Italy.

Abstract: Patients on maintenance hemodialysis face an elevated risk of parenteral Hepatitis C virus transmission due to frequent vascular access and prolonged healthcare exposure. We investigated HCV seroprevalence, viremia rates, and dialysis-related risk factors across outpatient renal units. Serum samples from 340 hemodialysis patients were tested for anti-HCV antibodies and quantitative HCV RNA, followed by viral genotyping. Anti-HCV antibodies were positive in 15.6 percent of patients, with active viremia confirmed in 77.4 percent of seropositive individuals, predominantly genotype 1b and genotype 4. Duration of hemodialysis exceeding three years, history of blood transfusions, and treatment across multiple dialysis centers were independent risk factors. Dedicated dialysis machines, strict infection control audits, and universal direct-acting antiviral therapy are recommended to achieve micro-elimination.

Keywords: Hepatitis C virus, Hemodialysis, Nosocomial transmission, Viremia, Direct-acting antivirals

Citation: Al-Thani M, Mensah K, Conti G (2025). Seroepidemiology and risk factors of Hepatitis C virus infection among patients undergoing maintenance hemodialysis. African Journal of Infectious Diseases Research, 11(4): 325–336. DOI: 10.46882/AJIDR/148728

Manuscript Timeline: Received: March 05, 2025; Revised: April 05, 2025; Accepted: April 21, 2025; Published: April 30, 2025

African Journal of Infectious Diseases Research | Vol. 11, No. 4, April 2025 | pp. 337-348

DOI: 10.46882/AJIDR/148729

Article Type: Research Article

Title: Clinical outcomes and antimicrobial susceptibility of Vibrio cholerae O1 isolates during seasonal cholera outbreaks

Names of Authors: Rashedul Islam¹*, Chidinma Nwosu², Anders Lindqvist³

Authors’ Affiliations: ¹Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh. ²Department of Medical Microbiology, University of Nigeria, Enugu, Nigeria. ³Department of Global Public Health, Lund University, Lund, Sweden.

Abstract: Cholera remains an acute diarrheal emergency capable of causing rapid dehydration and fatal hypovolemic shock within hours if untreated. This study characterized the clinical severity, serotype distribution, and antimicrobial resistance profiles of Vibrio cholerae during seasonal flooding outbreaks. Rectal swabs from 480 patients presenting with acute rice-water diarrhea were cultured on thiosulfate-citrate-bile salts-sucrose agar and tested for antimicrobial susceptibility. Toxigenic Vibrio cholerae O1 biotype El Tor, serotype Ogawa, was isolated in 44.8 percent of patients. Resistance to tetracycline and ciprofloxacin was observed in 64.2 percent and 51.6 percent of isolates, respectively, whereas susceptibility to azithromycin remained above 93.0 percent. Prompt oral and intravenous rehydration paired with azithromycin therapy and emergency water chlorination effectively curtailed case fatality rates.

Keywords: Vibrio cholerae, Cholera outbreak, Antimicrobial susceptibility, Dehydration, Water sanitation

Citation: Islam R, Nwosu C, Lindqvist A (2025). Clinical outcomes and antimicrobial susceptibility of Vibrio cholerae O1 isolates during seasonal cholera outbreaks. African Journal of Infectious Diseases Research, 11(4): 337–348. DOI: 10.46882/AJIDR/148729

Manuscript Timeline: Received: March 06, 2025; Revised: April 06, 2025; Accepted: April 22, 2025; Published: April 30, 2025

African Journal of Infectious Diseases Research | Vol. 11, No. 4, April 2025 | pp. 313-324

DOI: 10.46882/AJIDR/148727

Article Type: Research Article

Title: Biofilm formation and colistin resistance mechanisms among Acinetobacter baumannii isolates from ventilator-associated pneumonia

Names of Authors: Viktor Kovalenko¹*, Mei-Hua Lin², Omar Al-Farsi³

Authors’ Affiliations: ¹Department of Microbiology, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine. ²Department of Clinical Laboratory Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan. ³Department of Critical Care Medicine, Kuwait University, Kuwait City, Kuwait.

Abstract: Multidrug-resistant Acinetobacter baumannii is a formidable nosocomial pathogen in ventilated patients, with emerging colistin resistance severely restricting salvage therapy. This study characterized biofilm-forming capacity and molecular mechanisms of colistin resistance among respiratory isolates from ventilator-associated pneumonia cases. A total of 190 non-duplicate A. baumannii isolates underwent broth microdilution susceptibility testing, crystal violet biofilm assays, and sequencing of pmrAB and lpxACD operons. Extensively drug-resistant phenotypes were found in 76.8 percent of isolates, while colistin resistance was confirmed in 11.6 percent, driven primarily by mutations in pmrB and lipid A biosynthesis genes. Strong biofilm production was detected in 68.4 percent of strains and correlated significantly with persistent tracheal colonization. Strict ventilator bundle adherence and novel beta-lactam/beta-lactamase inhibitor combinations are urgently required.

Keywords: Acinetobacter baumannii, Ventilator-associated pneumonia, Colistin resistance, Biofilm formation, Nosocomial infection

Citation: Kovalenko V, Lin MH, Al-Farsi O (2025). Biofilm formation and colistin resistance mechanisms among Acinetobacter baumannii isolates from ventilator-associated pneumonia. African Journal of Infectious Diseases Research, 11(4): 313–324. DOI: 10.46882/AJIDR/148727

Manuscript Timeline: Received: March 04, 2025; Revised: April 04, 2025; Accepted: April 20, 2025; Published: April 30, 2025

African Journal of Infectious Diseases Research | Vol. 11, No. 4, April 2025 | pp. 301-312

DOI: 10.46882/AJIDR/148726

Article Type: Research Article

Title: Schistosoma haematobium infection intensity, bladder morbidity, and praziquantel efficacy in endemic freshwater fishing communities

Names of Authors: Abubakar Jibril¹*, Camille Moreau², Rafael Costa³

Authors’ Affiliations: ¹Department of Biological Sciences, Bayero University, Kano, Nigeria. ²Institute of Parasitology, University of Strasbourg, Strasbourg, France. ³Department of Tropical Pathology, Federal University of Minas Gerais, Belo Horizonte, Brazil.

Abstract: Urogenital schistosomiasis caused by Schistosoma haematobium leads to chronic hematuria, bladder fibrosis, and increased risk of squamous cell carcinoma in endemic areas. We evaluated infection prevalence, ultrasound-detected urinary tract pathology, and single-dose praziquantel cure rates among residents of freshwater fishing villages. Urine filtration microscopy and pelvic ultrasonography were performed on 495 participants aged five to fifty years. S. haematobium eggs were detected in 36.4 percent of subjects, with heavy infection intensity recorded in 14.1 percent and bladder wall thickening observed in 22.8 percent. Four weeks post-treatment, single-dose praziquantel achieved an overall parasitological cure rate of 84.4 percent and egg reduction rate of 95.1 percent. Periodic mass drug administration combined with focal snail control and clean water access remains crucial.

Keywords: Schistosoma haematobium, Urogenital schistosomiasis, Praziquantel efficacy, Bladder morbidity, Mass drug administration

Citation: Jibril A, Moreau C, Costa R (2025). Schistosoma haematobium infection intensity, bladder morbidity, and praziquantel efficacy in endemic freshwater fishing communities. African Journal of Infectious Diseases Research, 11(4): 301–312. DOI: 10.46882/AJIDR/148726

Manuscript Timeline: Received: March 03, 2025; Revised: April 03, 2025; Accepted: April 19, 2025; Published: April 30, 2025

African Journal of Infectious Diseases Research | Vol. 11, No. 4, April 2025 | pp. 289-300

DOI: 10.46882/AJIDR/148725

Article Type: Research Article

Title: Prevalence and macrolide resistance mutations of Mycoplasma pneumoniae in community-acquired atypical pneumonia

Names of Authors: Seung-Ho Lee¹*, Nadia Benjelloun², Patrick O'Sullivan³

Authors’ Affiliations: ¹Department of Internal Medicine, Korea University, Seoul, South Korea. ²Department of Microbiology, Ibn Tofail University, Kenitra, Morocco. ³Department of Respiratory Medicine, University College Cork, Cork, Ireland.

Abstract: Mycoplasma pneumoniae is a frequent cause of community-acquired respiratory tract infections in adolescents and young adults, with rising macrolide resistance complicating empirical therapy. In this study, we assessed the detection rate of M. pneumoniae and the prevalence of 23S rRNA point mutations conferring macrolide resistance. Throat swabs from 370 outpatients with radiologically confirmed atypical pneumonia were analyzed using real-time PCR and Sanger sequencing. M. pneumoniae DNA was detected in 23.5 percent of patients, and macrolide-resistant mutations—predominantly A2063G—were identified in 48.3 percent of positive specimens. Patients infected with resistant strains experienced significantly longer fever duration following initial azithromycin therapy. Rapid molecular resistance testing and timely switch to alternative doxycycline or fluoroquinolone regimens are recommended.

Keywords: Mycoplasma pneumoniae, Macrolide resistance, Atypical pneumonia, 23S rRNA mutation, Molecular diagnostics

Citation: Lee SH, Benjelloun N, O'Sullivan P (2025). Prevalence and macrolide resistance mutations of Mycoplasma pneumoniae in community-acquired atypical pneumonia. African Journal of Infectious Diseases Research, 11(4): 289–300. DOI: 10.46882/AJIDR/148725

Manuscript Timeline: Received: March 02, 2025; Revised: April 02, 2025; Accepted: April 18, 2025; Published: April 30, 2025

African Journal of Infectious Diseases Research | Vol. 11, No. 4, April 2025 | pp. 277-288

DOI: 10.46882/AJIDR/148724

Article Type: Research Article

Title: Cryptococcal antigenemia screening and mortality outcomes among antiretroviral-naive adults with advanced HIV disease

Names of Authors: Tendai Moyo¹*, Rachel Goldstein², Lucas Fernandez³

Authors’ Affiliations: ¹Department of Medicine, University of Zimbabwe, Harare, Zimbabwe. ²Division of Infectious Diseases, University of Toronto, Toronto, Canada. ³Department of Clinical Microbiology, University of Chile, Santiago, Chile.

Abstract: Cryptococcal meningitis accounts for a substantial proportion of AIDS-related deaths in individuals presenting with severe immunosuppression. This study evaluated the prevalence of asymptomatic cryptococcal antigenemia and the impact of preemptive fluconazole therapy on six-month survival. Serum cryptococcal antigen lateral flow assays were performed on 590 antiretroviral-naive adults with CD4 counts below 200 cells per microliter. Serum cryptococcal antigenemia was identified in 9.8 percent of participants, and lumbar puncture confirmed subclinical meningitis in 34.5 percent of antigen-positive patients. Six-month mortality was 15.5 percent among patients receiving preemptive antifungal therapy compared to 48.0 percent in historical unscreened cohorts. Routine reflex cryptococcal antigen screening at HIV diagnosis is essential to reducing early mortality.

Keywords: Cryptococcal antigenemia, Advanced HIV disease, Cryptococcal meningitis, Preemptive therapy, Lateral flow assay

Citation: Moyo T, Goldstein R, Fernandez L (2025). Cryptococcal antigenemia screening and mortality outcomes among antiretroviral-naive adults with advanced HIV disease. African Journal of Infectious Diseases Research, 11(4): 277–288. DOI: 10.46882/AJIDR/148724

Manuscript Timeline: Received: March 01, 2025; Revised: April 01, 2025; Accepted: April 17, 2025; Published: April 30, 2025